Inaktiver Wert

Andere Sprachen Bellerophon Therapeutics LLC Nasdaq

Aktien

Schlusskurs Nasdaq Andere Börsenplätze
-	-

04.03.	Bellerophon Therapeutics, Inc. gibt Rücktritt von Mary Ann Cloyd und Scott Bruder als Mitglieder des Verwaltungsrats bekannt	CI
2023	Bellerophon Therapeutics, Inc. kündigt Änderungen in der Geschäftsführung an	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

North American Morning Briefing : Stock Futures -2-	02.05.
North American Morning Briefing : More Tech -2-	25.04.
North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge	11.04.
North American Morning Briefing : Focus Turns to -2-	04.04.
North American Morning Briefing : Stocks Set for -2-	28.03.
Bellerophon Therapeutics, Inc. Announces Resignation of Mary Ann Cloyd and Scott Bruder as Members of Board of Directors	04.03.
Bellerophon Therapeutics, Inc. Announces Executive Changes	21.11.
Bellerophon Therapeutics, Inc. Announces Executive Changes	21.11.
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	20.11.
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14.11.
Bellerophon Therapeutics, Inc.(NasdaqCM:BLPH) dropped from S&P TMI Index	18.10.23
Bellerophon Therapeutics Insider Sold Shares Worth $111,776, According to a Recent SEC Filing	17.10.23
Bellerophon Therapeutics, Inc. Announces Resignation of Theodore Wang as a Member of the Company's Board	13.10.23
Bellerophon Therapeutics, Inc.(OTCPK:BLPH) dropped from NASDAQ Composite Index	13.10.23
North American Morning Briefing : Focus Shifts to -2-	21.08.23
Bellerophon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14.08.23
Investors Parse Inflation Data as Wall Street Set to Open Higher in Friday Trading	28.07.23
Bellerophon Therapeutics, Inc. Announces Resignation of Crispin Teufel as Board of Director	14.07.23
Bellerophon Therapeutics : Costs Associated with Exit/Disposal - Form 8-K	29.06.23
Bellerophon Therapeutics Announces Separation of Peter Fernandes as Chief Executive Officer, Effective July 15, 2023	29.06.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Bellerophon Therapeutics LLC Nasdaq

Aktien

Andere Sprachen

Filter